Stock Analysis
Cencora, Inc.COR
P/E 24.79×· 5Y range 18.72–1,414.96×· 43th percentile of history
Sector: Healthcare · Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
AnalystsStrong Buy21 analystsP/E 24.8× sits at the 43rd percentile of its 5.0978781656399725-year history.
Cash covers 19% of debt · Q3 2026.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Quality92
Mixed picture — no clear quality or value edge.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
- ✓Altman Z 3.7 — safe-zone balance sheet
- ✓ROE 81.0% — efficient capital deployment
- ✓Revenue CAGR 10.7% — durable top-line growth
What's happening with COR
Profile
Strong earnings quality.
How is each axis scored?
- Valuation62/100 · Moderate
- P/E vs own history (43th pct)12/25
- FCF yield (6.2%)20/25
- P/S (0.2x)25/25
- EV/EBIT (25.2x)5/25
- Growth57/100 · Moderate
- Revenue CAGR (10.7%)20/25
- Net income CAGR (0.2%)6/25
- EPS CAGR 5Y (1.9%)6/25
- Fwd implied growth (55.6%)25/25
- Profitability56/100 · Moderate
- ROIC (16.1%)20/25
- ROE (81.0%)25/25
- Net margin (0.8%)6/25
- Operating margin (0.9%)5/25
- Financial Health53/100 · Moderate
- Altman Z (3.68)25/25
- Current ratio (0.93)6/25
- Interest coverage (3.7x)10/25
- Net cash / debt (D/A 14%)12/25
- Quality92/100 · Strong
- Piotroski F (7/9)22/25
- Beneish M (-2.70)25/25
- FCF conversion (155%)25/25
- Margin stability (σ 5.2%)20/25
- Moat62/100 · Moderate
- ROIC >12% years (5/5 yrs)25/25
- Median gross margin (3.4%)0/25
- FCF-positive years (5/5 yrs)25/25
- Worst-year net margin (worst 0.5%)12/25
About Cencora, Inc.
Cencora is one of three leading domestic pharmaceutical wholesalers. Show more
It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Headquarters: CONSHOHOCKEN, PA · Employees: 51,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
62BP/E (TTM)24.8xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 18.7x–1415.0x · 43rd pct
P/FCF10.1xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.2%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -1.5%–8.7% · 47th pct
P/S (TTM)0.20xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 5Y history: 0.1x–200.3x · 85th pct
EV/EBIT25.2xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 12.7x–819.2x · 78th pct
EV/Sales0.2xA
Grade A: CheapEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.9xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio20.09xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.27C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.72%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio12.2%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
56CROIC16.1%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE81.0%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA3.3%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin0.8%D
Grade D: LowNet Income / Revenue
Operating Margin0.9%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin4.0%D
Grade D: LowGross Profit / Revenue
FCF Margin1.2%D
Grade D: LowFCF / Revenue
True FCF Margin1.2%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
57CRevenue CAGR10.7%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR0.2%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)1.9%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth55.6%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income5.7%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
53CAltman Z-Score3.68A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.93xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.57xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.7xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment2.9yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT3.8xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity4.47xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.19xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
92A+Piotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.70A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion154.7%A
Grade A: StrongFCF / Net Income
Margin Stability5.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue0.2%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover4.15xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Krikorian Lazarus Filed | Krikorian Lazarus | SellOpen market sale | -986 | |
SANCHEZ ROBERT E Filed | SANCHEZ ROBERT E | Grant / award | +275 | |
GREENBERG LON R Filed | GREENBERG LON R | SellOpen market sale | -1280 | |
Krikorian Lazarus Filed | Krikorian Lazarus | SellOpen market sale | -985 | |
Campbell Elizabeth S Filed | Campbell Elizabeth S | SellOpen market sale | -11300 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Tyler Lauren M Filed | Tyler Lauren M | Grant / award | +97 | |
NALLY DENNIS M Filed | NALLY DENNIS M | Grant / award | +113 | |
Cooper Ellen Filed | Cooper Ellen | Grant / award | +97 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
62BROIC >12% Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)3.4%D
Grade D: WeakMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor0.5%C
Grade C: ModerateWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$13.75
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$14.75
Cash & short-term investments per share (Finnhub)
Book Value / Share$15.99
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$14.46B
Total debt obligations (short + long term)
Cash & Equiv.$2.82B
Cash and short-term investments
Net Debt$11.65B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$3.24B
Shareholders' equity (book value)
Asset / Liability1.04xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$65.06B
Current Market Capitalization
Beta0.59B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: Cencora, Inc. (COR)
Cencora, Inc. meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 3.68 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.70 suggests a low likelihood of earnings manipulation.
- Takes ~2.9 years to repay net debt from free cash flow.
- Return on equity of 81.0% is well above the market average.
See how COR ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all COR moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 1 | Regular | 311.94 | +3.89% | 3.42 |
| Sep 30 | Pre-market | 297.70 | -3.22% | -2.22 |
Frequently Asked Questions about COR
What is the current Cencora, Inc. (COR) stock price?
COR is trading at $340.92 at the last market close, down 0.14% on the session. PreMarketPrice tracks COR pre-market, intraday and after-hours prices.
Is COR stock a buy right now?
PreMarketPrice's quantitative model rates Cencora, Inc.'s financial health at 53/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is COR stock overvalued?
Cencora, Inc. trades at a trailing P/E of 24.8 and our valuation score rates it 62/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Cencora, Inc. report earnings?
No confirmed earnings date is currently scheduled for COR. The Earnings section lists recent reports and updates as dates are announced.
What sector does Cencora, Inc. operate in?
Cencora, Inc. operates in the Healthcare sector, within the Wholesale-Drugs, Proprietaries & Druggists' Sundries industry. The Related Stocks section lists sector peers for comparison.
What does Cencora, Inc. do?
Cencora is one of three leading domestic pharmaceutical wholesalers.
About Cencora, Inc. (COR) Stock
Cencora, Inc. (COR) is a US-listed stock operating in the Healthcare sector, specifically the Wholesale-Drugs, Proprietaries & Druggists' Sundries industry. As of the latest update, Cencora, Inc. is trading at $340.92, down 0.14% on the day with a market capitalization of $65.1 billion. The financial health score for COR is 53/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for COR stock.
COR Stock Analysis & Key Metrics
On PreMarketPrice, you can track Cencora, Inc. (COR) across multiple dimensions:
- Pre-market price & movement: Real-time COR stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for COR with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Cencora, Inc. across multiple reporting periods.
- Financial health score: A composite score of 53/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for COR.
- Sector peers: Compare COR against 6 other healthcare stocks on key financial metrics.
Is COR a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Cencora, Inc. (COR) as an investment. The financial health score of 53/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Cencora, Inc. (COR) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.